Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
|Articles|July 1, 1998
Supplements and Featured Publications
- New and Emerging Therapies in the Treatment of Hypertension and Congestive Heart Failure
- Volume 4
- Issue 7 Suppl
How Far Have We Come in Treating Congestive Heart Failure?
Author(s)Bertram Pitt, MD
Advertisement
Articles in this issue
about 28 years ago
Participating Facultyabout 28 years ago
Gene Polymorphism Influences Response to Angiotensin Blockadeabout 28 years ago
New Drug Class Offers Benefits in Heart Failureabout 28 years ago
Clinical Implications of Differences Between Angiotensin II AntagonistsAdvertisement
Related to this article
Baseline biopsies separated 16 patients who later developed hepatocellular carcinoma from 32 matched controls a median 6.1 years ahead.
Patients with colorectal or ovarian cancer enrolled in a clinical trial have lower pharmacy and medical costs during the 9 months after trial initiation.
Survey findings show that although physicians view continuous glucose monitoring (CGM) as transformative, systemic barriers persist, leading to variable adoption across clinical practices.
Physicians to Discuss 2026 Oncology Care Index at Patient-Centered Oncology Care®, Premier Annual AJMC® Event Starting Today in Nashville |
60% of Community Physicians Say Clinical Trial Options Are Limited; 93% Say Pragmatic Designs Would Help
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Contributor: Congress Can Bring Mental Health Care to the 21st Century
4
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
5